Back to top

LACOG | Breast Cancer Group

Board

Dr. Gustavo Werutsky
Chair
Hospital São Lucas da PUCRS
Porto Alegre, Brazil

Dr. Max Senna Mano
Vice-chair
Grupo Oncoclínicas
São Paulo, Brazil

Dr. Paula Cabrera
Secretary
Instituto Nacional de Cancerología (INCAN)
Ciudad de Mexico, Mexico

Dr. José Bines
Scientific Director
Instituto Nacional de Câncer, INCA
Rio de Janeiro Brazil

Steering Committee

Brazil
Dr. Carlos Barrios
Grupo Oncoclínicas
Porto Alegre

Dr. Sérgio Simon
Hospital Israelita Albert Einstein
São Paulo

Dr. Daniela Rosa
Hospital Moinhos de Vento
Porto Alegre

Dr. Debora Gagliato
BP – A Beneficência Portuguesa de SP
São Paulo

Dr. Tomas Reinert
Oncoclínicas
Porto Alegre

Dr. Romualdo Barroso
DASA Oncologia
Brasília

Dr. Gustavo Marta
Hospital Sírio Libanês
São Paulo

Argentina
Dr. Gonzalo Gomez Abuin
Hospital Alemán
Buenos Aires

Dr. Luis Fein
Instituto de Oncologia de Rosário
Rosário

Mexico
Dr. Cynthia Villareal
Hospital Zambrano Hellion TecSalud
San Pedro Garza García

Peru
Dr. Denisse Bretel
GECO
Lima

Dr. Henry Gomez
Instituto Nacional de Enfermedades Neoplasicas
Lima

LACOG | Breast Cancer Group

Ongoing studies

GBECAM 0115 – AMAZONA III | Prospective evaluation of breast cancer at Brazilian institutions – Project AMAZONA III

LACOG 0115 – LORELEI | A Phase II Randomized, Double-Blind, Parallel Cohort Study of Neoadjuvant Letrozole + GDC-0032 versus Letrozole + Placebo in Post-Menopausal Women with ER+/HER2- Primary Breast Cancer.

LACOG 0221 – BRAVE | Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (LACOG 0221) – BRAVE Study OPEN FOR RECRUITMENT

LACOG 0413 – Male Breast Cancer | Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study.

LACOG 0419 – NEOSAMBA | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer OPEN FOR RECRUITMENT

LACOG 0615 – LATINABreast | A study to observe patients characteristics, treatment patterns and outcomes in patients with newly diagnosed breast cancer in Latin America.

LACOG 0715 – PALLAS | A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer 

LACOG 2118 – ALEXANDRA/IMpassion 030 | A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.

LACOG | Breast Cancer Group

Closed studies

LACOG 0111 – MGH | MGH – International Breast Cancer Collaborative Project: Determination of an Endocrine Responsive Metastatic Breast Cancer Signature.

LACOG 0312 – METASTATIC BC | Metastatic breast cancer in Brazil: characterization of patients and treatments.

LACOG 0414 | Evaluation of the attitude of premenopausal patients with breast cancer to the risk of loss of fertility caused by chemotherapy. | 

LACOG 0801 – GLICO | A randomized open-label, phase II study of lapatinib/capecitabine or lapatinib/vinorelbine or lapatinib/gemcitabine in subjects with Her2/neu amplified metastatic breast cancer patients progressing after taxanes treatment.

LACOG | Breast Cancer Group

Publications

LACOG | Breast Cancer Group

News